

Surgical Management of Infected Pancreatic Necrosis. Case Series in a Quaternary Care Hospital in Bogotá, Colombia, 2014-2021

Carlos Eduardo Rey-Chaves^{1*},  Alberto Ricaurte²,  Mónica Gómez³,  Pablo González⁴,  Felipe Castillo⁵ 

OPEN ACCESS

Citation:

Rey-Chaves CE, Ricaurte A, Gómez M, González P, Castillo F. Surgical Management of Infected Pancreatic Necrosis. Case Series in a Quaternary Care Hospital in Bogotá, Colombia, 2014-2021. *Rev Colomb Gastroenterol.* 2022;37(1):58-65. <https://doi.org/10.22516/25007440.778>

¹ General Practitioner, Hospital Universitario Mayor Méderi. Bogotá, Colombia.

² General Surgeon, Universidad El Rosario. Abdominal Wall and Laparoscopic Surgery Group, Hospital Universitario Mayor Méderi. Bogotá, Colombia.

³ General Practitioner, Universidad el Rosario. General Surgery Resident, Universidad El Rosario. Bogotá, Colombia.

⁴ General Practitioner, Hospital Universitario Mayor Méderi. Bogotá, Colombia.

⁵ Medicine Student, Universidad El Rosario. Bogotá, Colombia.

*Correspondence: Carlos Eduardo Rey-Chaves. carlosrey991@gmail.com

Received: 12/05/2021

Accepted: 14/09/2021



Abstract

Introduction: Pancreatitis is a frequent pathology in our environment, mostly related to benign biliary pathology. It can progress to severe forms in 10-15% of cases, where the pancreatic tissue becomes necrotic and forms large collections with risk of infection. We do not have epidemiological data about the incidence or management of this complication in Colombia. **Aim:** This study aims to study the prevalence of infected pancreatic necrosis and describe the cases identified in a quaternary care hospital between 2014 and 2021. **Materials and methods:** A cross-sectional observational study. We analyzed records of patients diagnosed with stage 2 pancreatitis. Those cases with infected pancreatic necrosis that underwent debridement plus laparoscopic and open surgical drainage at Hospital Universitario Mayor Méderi in Bogotá, Colombia, between January 2014 and January 2021 were studied. A convenience sampling was carried out without calculating the sample size. We collected the patients' demographic and clinical variables, performing a descriptive statistical analysis in Excel. Qualitative variables were described through absolute and relative frequencies, while quantitative ones were expressed through measures of central tendency and dispersion based on their distribution. **Results:** We analyzed 1020 episodes of pancreatitis, finding pancreatic necrosis in 30 patients, i.e., a period prevalence of 2.9%. Of the patients, 83% ($n = 25$) underwent open drainage, with 48% ($n = 12$) mortality. About laparoscopic management, the reduction in postoperative organ failure was 40% ($n = 2$), with a 30% shorter hospital stay than the open drainage approach. Those patients with a level of procalcitonin (PCT) lower than 1.8 ng/mL had less mortality. **Conclusions:** The laparoscopic approach shows promising results regarding final morbidity and mortality.

Keywords

Pancreatitis, laparoscopy, procalcitonin, necrosis, APACHE.

INTRODUCTION

Pancreatitis has been defined on multiple occasions over the years. However, in 2013, it was defined as “an acute process of the pancreas, triggered by the inappropriate activation of pancreatic enzymes, with tissue injury, and local inflammatory response with variable involvement of other tissues or distant organ systems.”⁽¹⁾ Data in the United States report

more than 300,000 admissions per year for this pathology. Mortality does not exceed 1% in mild admissions, and this figure can increase to 30% in severe cases. Mortality in these patients is, to a greater extent, a consequence of multi-organ failure or complications related to the difficult control of the local inflammatory process⁽²⁾.

One of the secondary complications to the inflammatory process of the pancreas to be highlighted is infected pancre-

atic necrosis, which historically has a mortality that can reach 70% with surgical management (mainly open). However, since the advent of minimally invasive approaches (fine-needle aspiration, percutaneous, endoscopic, or laparoscopic drainage), this figure has decreased to 30%⁽³⁾.

In 2013, a study compared open with laparoscopic management for debridement of infected pancreatic necrosis. A reduction from 63% to 41% in the rate of postoperative complications with laparoscopic management was shown. Postoperative organ failure also reduced their rates from 54% to 22%. The postoperative intensive care unit (ICU) requirement decreased from 54% to 29%, while the incidence of post-operative fistulas was lower than in open management, decreasing from 36% to 10%⁽⁴⁾. This same study considered an adequate time for surgical management by laparoscopy. An average of 30 days was evaluated with better results in terms of mortality and morbidity after this time⁽⁴⁾.

What has been described above reflects the high morbidity rates of this pathology. This is why, in recent years, strategies for the prediction of pancreatitis complications, such as the measurement of serum procalcitonin, have been proposed. Multiple studies have shown its usefulness in assessing patients with suspected local complications like infected pancreatic necrosis, and it could also have a predictive value to consider antibiotic onset and its prognosis⁽⁵⁻⁸⁾.

It has been recently proposed that the safest management with lower rates of postoperative complications should be laparoscopic⁽⁵⁾. However, there are no epidemiological data in Colombia on the incidence of complications after pancreatitis or the management indicated for infected pancreatic necrosis. However, there are data reported in the literature where the low incidence of complications is exposed, which in some case series reaches up to 8%^(1,9). In recent years, thanks to greater surgeon training, the laparoscopic management of these pathologies has increased in our institution. This study will describe the experience in the surgical management of infected pancreatic necrosis at the Hospital Universitario Mayor Méderi in Bogotá, Colombia.

MATERIALS AND METHODS

A descriptive observational case series study was conducted. An initial medical history review of patients diagnosed with pancreatitis was performed. Then, in a second step, those patients who underwent surgical drainage of infected pancreatic necrosis between 2014 and 2021 were analyzed. Patients with pancreatitis of a different origin to the biliary one were excluded. Sample size calculation was not performed. All patients meeting the inclusion criteria were considered. Demographic, clinical, surgical, imaging, and paraclinical variables were collected. A descriptive analysis was carried out: qualitative variables were pre-

sented in absolute and relative frequencies, and quantitative variables were formulated with dispersion and central tendency measures according to normality.

Diagnosis of complication

Those patients who had torpid progression after the first 96 hours of comprehensive medical management were taken as suspects for a possible local complication of pancreatitis. Then, by performing imaging studies (abdomen tomography and abdominal magnetic resonance imaging), local complications were confirmed. Additionally, those patients who presented signs of systemic inflammatory response, sepsis, and radiological evidence of gas within the collection were considered infected. The diagnosis of infected pancreatic necrosis was then configured.

RESULTS

A total of 1020 medical records of patients diagnosed with acute pancreatitis were analyzed between 2014 and 2021. 33 patients who presented infected pancreatic necrosis as a major complication were identified and taken to surgical drainage by the institution's General Surgery service. Three patients were excluded, two of them due to traumatic pancreatitis and one because of secondary pancreatitis to hypertriglyceridemia.

A period prevalence of pancreatic necrosis of 2.9% was identified in relation to all pancreatitis analyzed. As for the population with infected pancreatic necrosis, most of them are male (70%; $n = 21$) with an average age of 56 years (**Table 1**). 93% of patients were studied preoperatively using an abdominal computed tomography with contrast. Antibiotic management prior to any intervention in all patients was initiated using multiple antibiotic therapies in 53% of them (**Table 2**). It is important to emphasize that in the ICU, antifungals were initiated prophylactically in 30% of patients, following institutional protocols adjusted to international scales of risk prediction for fungal colonization (isolating in 28% of patients). The entire sample that was subjected to surgical drainage was cultured from the collection. More than one germ was isolated in 33% of the evaluated samples, and in 26% of the cases, it was negative (**Table 3**).

In terms of invasive interventions for managing complications, it was found that, in all cases, patients were assessed by interventional radiology to perform interventions prior to surgical management. The open surgical approach was evidenced in 83% of cases, whereas 16% of cases were managed laparoscopically (**Figure 1**).


Regarding postoperative complications, 73% of patients ($n = 22$) did not present any. Out of 27% of patients with

Table 1. Comorbidities

Comorbidities	N	%
Denies comorbidities	13	34.2
Diabetes <i>mellitus</i> type 2	4	10.5
Chronic obstructive pulmonary disease	3	10.5
Chronic kidney disease	0	0
Arterial hypertension	7	18.4
Coronary disease	1	2.6
Immunosuppression	1	2.6
Others (peptic acid disease, hypothyroidism)	8	21.05
More than two comorbidities	7	23.3
Only one comorbidity	10	33.3

Table 2. Antibiotic therapy

Antibiotic	N	%
Meropenem	27	90
Ampicillin/sulbactam	3	10
Vancomycin	7	23.3
Caspofungin with fluconazole	9	30
Metronidazole	1	3.3
Monotherapy	14	46.6
Multiple therapies	16	53.3

**Figure 1.** Approach throughout the years.**Table 3.** Isolated microorganisms

Microorganism	N	%
<i>E. coli</i>	6	20
<i>P. aeruginosa</i>	2	6.6
<i>K. pneumoniae</i>	6	20
<i>K. oxytoca</i>	2	6.6
<i>E. faecalis</i>	2	6.6
<i>E. faecium</i>	4	13.3
<i>E. casseliflavus</i>	1	3.3
<i>E. gallinarum</i>	1	3.3
<i>A. baumannii</i>	2	6.6
<i>S. anginosus</i>	1	3.3
<i>S. epidermidis</i>	1	3.3
<i>S. haemolyticus</i>	1	3.3
<i>C. freundii</i>	1	3.3
<i>K. ascorbata</i>	1	3.3
<i>Candida albicans</i>	4	13.3
<i>Candida glabrata</i>	3	10
<i>Candida tropicalis</i>	1	3
Polibacterial	10	33.3
Bacterial with fungal	6	20
Monobacterial	6	20
Negative	8	26

complications, the most frequent condition was the pancreatic fistula. Postoperative outcomes such as reinterventions, total hospital stay, postoperative hospital stay in ICU, and mortality in those patients undergoing surgical management by laparoscopy are described in **Table 4**.

As part of an additional analysis, the use of procalcitonin was evaluated. We were able to observe that for values < 1.8 ng/dL, mortality was 8.33 (n = 1), compared with values > 1.8 ng/dL where it was 60% (n = 6). Its behavior is

Table 4. Postoperative variables

Approach	Mortality (n)	Hospital stay in an average of days (n)	Stay in POP intensive care unit in a maximum of days	Reinterventions (n)	Procalcitonin > 1,8
Open	25 (12)	2-132	0-65*	25 (19)	25 (8)
Laparoscopic	5 (0)	9-40	2-9	5 (0)	5 (2)

POP: Postoperative. *Day 0 for mortality.

described in **Table 5**. Additionally, as we do not have statistical data on this pathology in Latin America, we evaluated the institution's prevalence of infected pancreatic necrosis. In the 2014–2021 period, there were 1020 cases of pancreatitis (this data could be biased due to the institution's ICD-10 diagnostic records). Out of these, 30 patients presented infected pancreatic necrosis as a major complication of pancreatitis, equivalent to 2.9% of period prevalence. This is not far from what is described in the literature (1.2%).

Table 5. Paraclinical variables of patients with infected pancreatic necrosis

Paraclinical variable	N	%
Leukocytes		
- < 4000	0	0
- 4001-10 000	11	36
- 10 001-15 000	7	23
- 15 001-18 000	5	16
- > 18 000	7	23
Bilirubin		
- < 1.8	20	66
- 1.9-4.0	8	26
- > 4.9	2	6.6
Alkaline phosphatase		
- < 150	16	53
- 150-300	19	33
- > 300	4	13
Procalcitonin		
- < 1.8	12	40
- > 1.8	10	33
Not taken	8	26

DISCUSSION

The management of acute pancreatitis complications has steadily evolved for about 20 years. Initially, open management was perhaps the only approach. It showed morbidity rates ranging from 43% to 89% and mortality rates as high

as 39% in some case series. However, management through minimally invasive techniques has increased recently and showed better results in terms of morbidity and mortality compared to open management, such as in reinterventions (34% vs. 12%), pancreatic fistula (10% vs. 7%), mortality (18% vs. 27%) and hospital stay (40d vs. 49d), respectively, as reported in the literature⁽¹⁰⁻¹⁶⁾.

Additionally, the “step-by-step” management of infected pancreatic necrosis has been proposed. It establishes compliance with certain interventions in order to defer a surgical procedure that could add morbidity and even mortality to the patient⁽³⁾. In some case series, minimally invasive “step-by-step” management has demonstrated efficacy in about 40% of patients, reducing the need for surgical management⁽³⁾. 100% of our population was referred to the interventional radiology or gastroenterology service to assess the relevance of fine-needle aspiration, percutaneous drainage, or endoscopic drainage of the pancreatic lesion (following the “step-by-step” management of the infected pancreatic necrosis)⁽³⁾.

In 20% of cases, patients underwent percutaneous drainage of the lesion first, and 3% underwent fine-needle aspiration. The rest of our population required surgical management due to technical difficulties of the percutaneous/endoscopic procedure. We can evidence that percutaneous management was effective in 23% (n = 7) of our patients and prevented an eventual surgical procedure. This is not far from what was reported in the literature (35%–40%)⁽³⁾.

However, in surgical terms, the laparoscopic approach has had significant advances in recent years mainly because of greater surgeon training (**Figure 1**). This results in better use of the approach. The evidence in the world literature reports better results, such as postoperative ICU stay, mortality, reinterventions, and complications such as pancreatic and enterocutaneous fistula. In our study, laparoscopic management presented 0% mortality with a mean follow-up of 1 year. Similar results are reported in the literature, which are reported for minimally invasive approaches of 9%^(1,3,9,10) compared to open management, where we

observed a rate of 48% (results comparable to those documented in the literature of 45%–50%)^(4,9,11).

In terms of postoperative organ failure, laparoscopic management in the population decreased by about 40% from day 1 to day 2 and 20% from day 2 to day 3. These results are not evidenced in any study evaluated in the bibliography. However, in a series of cases, postoperative *de novo* organ failure was evaluated and decreased by about 25% in patients with minimally invasive approaches⁽³⁾.

Additionally, we observed that procalcitonin (PCT) was used as an infection marker in most of our patients (73%) prior to imaging studies. We established a 1.8 ng/mL cutoff point (taken from previous studies)^(5,6,8,12) and, given recent advances with PCT as a useful biomarker for antibiotic initiation in pancreatitis, we wanted to observe its behavior compared to the *computed tomography severity index* (CTSI) and mortality. PCT > 1.8 ng/mL was found to be related to a higher CTSI. In terms of mortality, we found that a PCT < 1.8 ng/mL was associated with lower mortality rates (out of 12 patients with PCT < 1.8 ng/mL, 11 had no mortality). This could reflect a possible relationship between procalcitonin elevation and pancreatic inflammatory status.

In microbiological terms, patients had a polymicrobial behavior with a predisposition to enterobacteriae colonization, which is related to what is reported in the literature^(7,13,14). Regarding antibiotics, there is a tendency to use carbapenems (more precisely meropenem) as described in international guides and recent studies. These studies indicate that their use, or that of ertapenem, has favorable results to control these infections^(5,7,8,14-41).

Given the above, as observed in our results, and considering what has been reported in the world literature, the minimally invasive laparoscopic approach shows promising results as it reduces, in considerable terms, the morbidity and mortality of our patients and hospital costs due to a decrease in general hospital stay and ICU. However, these results depend on multiple additional factors, such as the patient's age, comorbidities, and the surgeon's training, which is not assessable in the present study due to its observational nature.

The observed behavior of procalcitonin is promising. Recently, studies in the UK, such as PROCAP, sought to establish a relationship between PCT and the initiation of antibiotic therapy in pancreatitis^(7,17-25,42-45). Although no study adequately reveals a predictive capacity of procalcitonin in this pathology^(5,7,8,16,26-41), we can evidence a trend of this marker as a predictor of mortality in our study. However, more prospective studies are needed to confirm this hypothesis.

LIMITATIONS OF THE STUDY

The observational and retrospective nature prevents the hypotheses formulation with statistical power. However, based on the observational behavior of the results, it invites to generate hypotheses to be used in prospective studies that confirm what has been evaluated in this series of cases.

CONCLUSIONS

Currently, infected pancreatic necrosis is still a difficult pathology to manage surgically and a challenge for the surgeon. Stepwise and minimally invasive management should be of choice, always trying to avoid a surgical procedure that, if necessary, should be addressed laparoscopically since it presents better results in terms of mortality, morbidity, and general hospital and ICU stay. Procalcitonin could be a useful biomarker for predicting complications or mortality in these patients. However, more prospective studies are needed.

Conflicts of interest

None of the authors claims to have conflicts of interest.

Acknowledgments

Thanks to the General Surgery service of Hospital Universitario Mayor Méderi.

REFERENCES

1. Senthil Kumar P, Ravichandran P, Jeswanth S. Case matched comparison study of the necrosectomy by retroperitoneal approach with transperitoneal approach for necrotizing pancreatitis in patients with CT severity score of 7 and above. *Int J Surg*. 2012;10(10):587-92. <https://doi.org/10.1016/j.ijssu.2012.09.027>
2. Tyberg A, Karia K, Gabr M, Desai A, Doshi R, Gaidhane M, et al. Management of pancreatic fluid collections: A comprehensive review of the literature. *World J Gastroenterol*. 2016;22(7):2256-70. <https://doi.org/10.3748/wjg.v22.i7.2256>
3. Li A, Cao F, Li J, Fang Y, Wang X, Liu D, et al. Step-up mini-invasive surgery for infected pancreatic necrosis: Results from prospective cohort study. *Pancreatology*. 2016;16(4):508-14. <https://doi.org/10.1016/j.pan.2016.03.014>

4. Tu Y, Jiao H, Tan X, Sun L, Zhang W. Laparotomy versus retroperitoneal laparoscopy in debridement and drainage of retroperitoneal infected necrosis in severe acute pancreatitis. *Surg Endosc*. 2013;27(11):4217-23. <https://doi.org/10.1007/s00464-013-3026-0>
5. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. *Lancet*. 2010;375(9713):463-74. [https://doi.org/10.1016/S0140-6736\(09\)61879-1](https://doi.org/10.1016/S0140-6736(09)61879-1)
6. Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: Systematic review. *Surgery*. 2009;146(1):72-81. <https://doi.org/10.1016/j.surg.2009.02.013>
7. Chen HZ, Ji L, Li L, Wang G, Bai XW, Cheng CD, et al. Early prediction of infected pancreatic necrosis secondary to necrotizing pancreatitis. *Medicine (Baltimore)*. 2017;96(30):e7487. <https://doi.org/10.1097/MD.0000000000007487>
8. de Jong E, van Oers JA, Beishuizen A, Girbes AR, Nijsten MW, de Lange DW. Procalcitonin to guide antibiotic stewardship in intensive care - Authors' reply. *Lancet Infect Dis*. 2016;16(8):889-90. [https://doi.org/10.1016/S1473-3099\(16\)30210-9](https://doi.org/10.1016/S1473-3099(16)30210-9)
9. Sarr MG, Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, et al. The new revised classification of acute pancreatitis 2012. *Surg Clin North Am*. 2013;93(3):549-62. <https://doi.org/10.1016/j.suc.2013.02.012>
10. Wroński M, Cebulski W, Witkowski B, Jankowski M, Kluciński A, Krasnodebski IW, et al. Comparison between minimally invasive and open surgical treatment in necrotizing pancreatitis. *J Surg Res*. 2017;210:22-31. <https://doi.org/10.1016/j.jss.2016.10.022>
11. Olakowski M, Dranka-Bojarowska D, Szlachta-Światkowska E, Lekstan A, Lampe P. Management of necrotizing pancreatitis: Flexible approach depending on intra-operative assessment of necrosis. *Acta Chir Belg*. 2006;106(2):172-6. <https://doi.org/10.1080/00015458.2006.11679865>
12. Schwender BJ, Gordon SR, Gardner TB. Risk factors for the development of intra-abdominal fungal infections in acute pancreatitis. *Pancreas*. 2015;44(5):805-7. <https://doi.org/10.1097/MPA.0000000000000334>
13. Götzinger P, Sautner T, Kriwanek S, Beckerhinn P, Barlan M, Armbruster C, et al. Surgical treatment for severe acute pancreatitis: Extent and surgical control of necrosis determine outcome. *World J Surg*. 2002;26(4):474-8. <https://doi.org/10.1007/s00268-001-0252-8>
14. van Baal MC, Bollen TL, Bakker OJ, van Goor H, Boermeester MA, Dejong CH, et al. The role of routine fine-needle aspiration in the diagnosis of infected necrotizing pancreatitis. *Surgery*. 2014;155(3):442-8. <https://doi.org/10.1016/j.surg.2013.10.001>
15. Mowbray NG, Ben-Ismael B, Hammada M, Shingler G, Al-Sarireh B. The microbiology of infected pancreatic necrosis. *Hepatobiliary Pancreat Dis Int*. 2018;17(5):456-60. <https://doi.org/10.1016/j.hbpd.2018.08.007>
16. De Waele JJ, Rello J, Anzueto A, Moreno R, Lipman J, Sakr Y, et al. Infections and use of antibiotics in patients admitted for severe acute pancreatitis: Data from the epic II study. *Surg Infect (Larchmt)*. 2014;15(4):394-8. <https://doi.org/10.1089/sur.2012.228>
17. Mourad MM, Evans RPT, Kalidindi V, Navaratnam R, Dvorkin L, Bramhall SR. Prophylactic antibiotics in acute pancreatitis: Endless debate. *Ann R Coll Surg Engl*. 2017;99(2):107-12. <https://doi.org/10.1308/rcsann.2016.0355>
18. John BJ, Swaminathan S, VenkataKrishnan L, Singh GS, Krishnaveni G, Mohandas N, et al. Management of infected pancreatic necrosis-the "step up" approach and minimal access retroperitoneal pancreatic necrosectomy. *Indian J Surg*. 2015;77(1):125-7. <https://doi.org/10.1007/s12262-014-1197-0>
19. Wolbrink DRJ, Kolwijck E, Ten Oever J, Horvath KD, Bouwense SAW, Schouten JA. Management of infected pancreatic necrosis in the intensive care unit: A narrative review. *Clin Microbiol Infect*. 2020;26(1):18-25. <https://doi.org/10.1016/j.cmi.2019.06.017>
20. Roberts SE, Morrison-Rees S, John A, Williams JG, Brown TH, Samuel DG. The incidence and aetiology of acute pancreatitis across Europe. *Pancreatol*. 2017;17(2):155-65. <https://doi.org/10.1016/j.pan.2017.01.005>
21. Trikuladhanathan G, Wolbrink DRJ, van Santvoort HC, Mallery S, Freeman M, Besselink MG. Current concepts in severe acute and necrotizing pancreatitis: An evidence-based approach. *Gastroenterology*. 2019;156(7):1994-2007. <https://doi.org/10.1053/j.gastro.2019.01.269>
22. van Santvoort HC, Bakker OJ, Bollen TL, Besselink MG, Ahmed Ali U, Schrijver AM, et al. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. *Gastroenterology*. 2011;141(4):1254-63. <https://doi.org/10.1053/j.gastro.2011.06.073>
23. Petrov MS, Chong V, Windsor JA. Infected pancreatic necrosis: Not necessarily a late event in acute pancreatitis. *World J Gastroenterol*. 2011;17(27):3173-6. <https://doi.org/10.3748/wjg.v17.i27.3173>
24. Besselink MG, van Santvoort HC, Boermeester MA, Nieuwenhuijs VB, van Goor H, Dejong CH, et al. Timing and impact of infections in acute pancreatitis. *Br J Surg*. 2009;96(3):267-73. <https://doi.org/10.1002/bjs.6447>
25. Buchler M, Malfertheiner P, Friess H, Isenmann R, Vanek E, Grimm H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. *Gastroenterology*. 1992;103(6):1902-8. [https://doi.org/10.1016/0016-5085\(92\)91450-i](https://doi.org/10.1016/0016-5085(92)91450-i)
26. Ullmann AJ, Aguado JM, Arikian-Akdaglı S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017

- ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect.* 2018;24(Suppl 1):e1-e38.
<https://doi.org/10.1016/j.cmi.2018.01.002>
27. Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, et al. Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: The ACTIVE trial. *Clin Infect Dis.* 2019;68(12):1981-9.
<https://doi.org/10.1093/cid/ciy827>
28. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open label trial. *Lancet Infect Dis.* 2016;16(7):819-27.
[https://doi.org/10.1016/S1473-3099\(16\)00053-0](https://doi.org/10.1016/S1473-3099(16)00053-0)
29. Maravi-Poma E, Gener J, Álvarez-Lerma F, Olaechea P, Blanco A, Dominguez Munoz JE, et al. Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: A prospective, randomized, multicenter study comparing two regimens with imipenem-cilastatin. *Intensive Care Med.* 2003;29(11):1974e80.
<https://doi.org/10.1007/s00134-003-1956-z>
30. Akshintala VS, Saxena P, Zaheer A, Rana U, Hutfless SM, Lennon AM, et al. A comparative evaluation of outcomes of endoscopic versus percutaneous drainage for symptomatic pancreatic pseudocysts. *Gastrointest Endosc.* 2014;79(6):921-8.
<https://doi.org/10.1016/j.gie.2013.10.032>
31. Mouli VP, Sreenivas V, Garg PK. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: A systematic review and meta-analysis. *Gastroenterology.* 2013;144(2):333-40.e2.
<https://doi.org/10.1053/j.gastro.2012.10.004.e2>
32. Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. *Lancet Infect Dis.* 2016;16(7):847-856.
[https://doi.org/10.1016/S1473-3099\(16\)00065-7](https://doi.org/10.1016/S1473-3099(16)00065-7)
33. Rodríguez JR, Razo AO, Targarona J, Thayer SP, Rattner DW, Warshaw AL, et al. Debridement and closed packing for sterile or infected necrotizing pancreatitis: Insights into indications and outcomes in 167 patients. *Ann Surg.* 2008;247(2):294-9.
<https://doi.org/10.1097/SLA.0b013e31815b6976>
34. Fritz S, Hackert T, Hartwig W, Rossmanith F, Strobel O, Schneider L, et al. Bacterial translocation and infected pancreatic necrosis in acute necrotizing pancreatitis derives from small bowel rather than from colon. *Am J Surg.* 2010;200(1):111-7.
<https://doi.org/10.1016/j.amjsurg.2009.08.019>
35. Moka P, Goswami P, Kapil A, Xess I, Sreenivas V, Saraya A. Impact of antibiotic-resistant bacterial and fungal infections in outcome of acute pancreatitis. *Pancreas.* 2018;47(4):489-94.
<https://doi.org/10.1097/MPA.0000000000001019>
36. Da Costa DW, Boerma D, van Santvoort HC, Horvath KD, Werner J, Carter CR, et al. Staged multidisciplinary step-up management for necrotizing pancreatitis. *Br J Surg.* 2014;101(1):e65-79. <https://doi.org/10.1002/bjs.9346>
37. Easler JJ, Zureikat A, Papachristou GI. An update on minimally invasive therapies for pancreatic necrosis. *Expert Rev Gastroenterol Hepatol.* 2012;6(6):745-53.
<https://doi.org/10.1586/egh.12.48>
38. Flint RS, Windsor JA. The role of the intestine in pathophysiology and management of severe acute pancreatitis. *HPB.* 2003;5(2):69-85.
<https://doi.org/10.1080/13651820310001108>
39. van Brunschot S, van Grinsven J, Voermans RP, Bakker OJ, Besselink MG, Boermeester MA, et al. Transluminal endoscopic step-up approach versus minimally invasive surgical step-up approach in patients with infected necrotizing pancreatitis (TENSION trial): Design and rationale of a randomized controlled multicenter trial [ISRCTN09786711]. *BMC Gastroenterol.* 2013;13:161.
<https://doi.org/10.1186/1471-230X-13-161>
40. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Pancreatitis Classification Working Group. Classification of acute pancreatitis - 2012: Revision of the Atlanta classification and definitions by international consensus. *Gut.* 2013;62(1):102-11.
<https://doi.org/10.1136/gutjnl-2012-302779>
41. Sing VK, Wu BU, Bollen TL, Repas K, Maurer R, Mortele KJ, et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. *Clin Gastroenterol Hepatol.* 2009;7(11):1247-51.
<https://doi.org/10.1016/j.cgh.2009.08.012>
42. Baronia AK, Azim A, Ahmed A, Gurjar M, Marak RS, Yadav R, et al. Invasive candidiasis in severe acute pancreatitis: Experience from a tertiary care teaching hospital. *Indian J Crit Care Med.* 2017;21(1):40-5.
<https://doi.org/10.4103/0972-5229.198325>
43. Schmidt PN, Roug S, Hansen EF, Knudsen JD, Novovic S. Spectrum of microorganisms in infected walled-off pancreatic necrosis e impact on organ failure and mortality. *Pancreatology.* 2014;14(6):444-9.
<https://doi.org/10.1016/j.pan.2014.09.001>
44. Dellinger EP, Tellado JM, Soto NE, Ashley SW, Barie PS, Dugernier T, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: A randomized, double-blind, placebo-controlled study. *Ann Surg.* 2007;245(5):674-83.
<https://doi.org/10.1097/01.sla.0000250414.09255.84>
45. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis.* 2010;50(2):133-64.
<https://doi.org/10.1086/649554>